FDA Approves Isatuximab, Carfilzomib, Dexamethasone Combination for RRMM

April 3rd 2021, 9:30am


Multiple myeloma is the second most common blood cancer, affecting more than 130,000 US patients.

The Impact of Sickle Cell Disease Severity on HRQOL and Economic Outcomes

April 1st 2021, 12:40pm


Disease severity was strongly associated with health-related quality of life, moderately associated with use of disability insurance, and weakly associated with household income for patients with sickle cell disease.

Many Options, Many Updates to NCCN Guidelines in Multiple Myeloma

March 24th 2021, 5:45pm


Updates to the NCCN Guidelines in multiple myeloma reflect recent trial results, giving clinicians and patients many choices.

Lenacapavir Against HIV Demonstrates Ongoing Potential

March 16th 2021, 5:37pm


The safety and effectiveness of the long-acting agent is backed by data from trials of the drug among treatment-experienced individuals living with HIV-1 whose viral load is on the rise due to other regimens failing. Investigation continues among these patients, as well as treatment-naive patients.

Report Describes Case of Improved Outcome in MM With Personalized Medicine

March 6th 2021, 7:00pm


Researchers describe the case of an older patient who underwent myeloma drug sensitivity testing as part of an effort to identify the therapies most likely to produce a response in this difficult-to-treat population.

Marrow Lymphocyte Patterns After ASCT May Have Prognostic Value in MM

March 5th 2021, 2:30pm


Patients with multiple myeloma (MM) often relapse over time despite initially achieving a complete response without minimal residual disease following induction treatment, leaving questions about changes in the immune system and the prognosis of the disease.

Trial of Anti-BCMA ide-cel for RRMM Leads to Undetectable Disease in 33% of Patients

February 27th 2021, 8:30pm


More than 2 years after treatment, some of the patients with relapsed/refractory multiple myeloma have yet to see a relapse. An FDA decision on the therapy is expected within a month.

FDA Clears Peptide-Drug Conjugate for RRMM

February 27th 2021, 4:15am


The peptide-drug conjugate rapidly delivers an alkylating payload into tumor cells.

Combination Treatment Maintains Quality of Life in Relapsed/Refractory MM

February 20th 2021, 11:00pm


Health-related quality of life was maintained when treating relapsed/refractory multiple myeloma (RRMM) with daratumumab in combination with bortezomib and dexamethasone.

Sustained MRD Negativity Predictive of Long-term Outcomes in RRMM

February 16th 2021, 5:42pm


Sustained minimal residual disease (MRD) negativity may predict long-term outcomes in relapsed/refractory multiple myeloma (RRMM), and daratumumab-based combinations show higher rates of sustained MRD negativity compared with the standard of care.